Published online Aug 26, 2019. doi: 10.12998/wjcc.v7.i16.2269
Peer-review started: March 26, 2019
First decision: May 24, 2019
Revised: July 4, 2019
Accepted: July 27, 2019
Article in press: July 27, 2019
Published online: August 26, 2019
Processing time: 153 Days and 9.6 Hours
Surveillance of hepatocellular carcinoma (HCC) has been proposed and recommended in clinical guidelines, in order to obtain earlier diagnosis but it is still controversial and it is not accepted worldwide.
Emerging populations like non-alcoholic fatty liver disease patients or hepatitis C virus (HCV) after achieving sustained viral response (SVR) are at risk of developing HCC. Should they be screened? What is the ideal screening tool attending cost-effectiveness?
Support the surveillance programs in patients at risk of developing HCC because of the cost-effectiveness of early diagnosis.
Systematic review of recent literature of surveillance (tools, interval, cost-benefit, target population) and the role of imaging diagnosis (radiological non-invasive diagnosis, optimal modality and agents) of HCC.
The benefits of surveillance of HCC, mainly with ultrasonography, have been assessed in several prospective and retrospective analysis. Surveillance of HCC permits diagnosis in early stages allowing better access to curative treatment and increased life expectancy in patients at risk.
The actual evidence supports the recommendation of performing surveillance of HCC in patients with cirrhosis or advanced fibrosis of any etiology susceptible of treatment, using ultrasonography every 6 mo. In some populations of non-cirrhotic hepatitis B virus patients the screening can be cost-effective. The diagnosis evaluation of HCC can be established based on noninvasive imaging criteria in patients with cirrhosis.
Further studies need for evaluating the cost-effectiveness of screening in emerging populations like non-cirrhotic non-alcoholic fatty liver disease patients or HCV who achieved SVR. Utility of hepatospecific contrasts needs further evaluation.